Please check your internet connection and try again.
# Hepa-Merz (L-Ornithine L-Aspartate / LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two endogenous amino acids. It serves as a substrate for the urea cycle and glutamine synthesis, assisting in the detoxification of ammonia in the liver and muscle tissue.
## Primary Indications
* Treatment of hyperammonemia in liver disease (acute or chronic hepatitis, cirrhosis).
* Management of hepatic encephalopathy (latent or overt).
## Adult Dosing
* **Oral (Granules):** 3g to 6g daily, divided into 3 doses. Mix contents with liquid and take after meals.
* **Intravenous (Infusion):** Up to 4 ampoules (40g) daily in severe cases. Rate should not exceed 5g per hour. Must be diluted in IV fluids (e.g., 5% dextrose, 0.9% NaCl).
* **Maximum:** Follow local institutional protocol; safety data regarding chronic high-dose parenteral use is limited.
## Pediatric Dosing
Established pediatric dosing is limited. Use is generally off-label and not routinely recommended without specialist hepatology guidance. If used, dosing is weight-based (typically 0.1–0.15g/kg/day); consult institutional guidelines and pediatric prescribing references.
## Dose Adjustments
* **Renal Impairment:** Exercise caution in patients with severe renal impairment (Creatinine > 3 mg/dL). Plasma clearance ofLOLAmay be reduced.
* **Hepatic Impairment:** No dose reduction required; however, monitor for signs of fluid overload in patients with severe ascites or renal dysfunction.
## Contraindications
* Hypersensitivity to the active ingredients.
* Severe renal impairment (Creatinine > 3 mg/dL, though absolute thresholds may vary by protocol).
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, stomach pain, flatulence, and diarrhea.
* **Systemic:** Rare occurrences of arthralgia or hypersensitivity reactions.
* **Infusion-related:** Injection site irritation (if extravasated).
## Key Drug Interactions
* Minimal clinical interactions documented.
* Caution when used alongside medications that cause excessive ammonia elevation (e.g., valproic acid).
## Monitoring
* **Ammonia Levels:** Serial blood ammonia monitoring to assess treatment efficacy.
* **Renal Function:** Monitor electrolytes and creatinine, especially in IV administration.
* **Clinical Status:** Assessment of mental status (NCT-A or psychometric testing) for hepatic encephalopathy improvement.
## Clinical Pearls
* LOLA is considered an adjunctive therapy; it does not replace standard-of-care treatments for hepatic encephalopathy such as lactulose or rifaximin.
* If using IV, monitor for fluid overload; the sodium/fluid content of the diluent must be accounted for in decompensated cirrhotic patients.
* Ensure granules are fully dissolved in sufficient fluid (e.g., 200mL) to minimize GI local irritation.
***
*Disclaimer: This information is for educational purposes only. Clinical practice and institutional protocols vary significantly. Always verify the most current prescribing information from the manufacturer and consult local clinical pharmacy or hepatology guidelines before prescribing or administering medication.*
